New combo attack on lymphoma shows promise in early trial
NCT ID NCT03035331
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the safest dose and see if the combination could shrink tumors. Only 11 people took part, so the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dendritic cell therapy, pembrolizumab (Keytruda), and cryoablation
- What this could lead to
- If it works, this combination could offer a new treatment option for patients with non-Hodgkin lymphoma that has come back after other therapies.
- What could go wrong
- This was a very small, early-phase trial with only 11 participants, so results may not apply to everyone. The combination also carries risks of serious side effects like immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?